Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 11C-choline PET/CT and PSA kinetics.

Literature DB >> 23579864

11C-choline PET/CT and PSA kinetics.

Abstract

The role of PET/CT with radiolabelled (18)F-choline or (11)C-choline in patients with prostate cancer after primary treatment has not been established yet and there are no guidelines on the appropriate use of this emerging modality. According to the literature, choline PET/CT may have a role in restaging the disease in patients with biochemical relapse for the detection of local and/or lymph node and/or distant recurrence. The aim of this brief review is to summarize the results of the most relevant published studies with particular focus on the relationship between prostate-specific antigen levels and kinetics and the sensitivity of choline PET/CT for optimizing the selection of patients who may benefit the most from this diagnostic procedure, especially early after biochemical recurrence.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23579864 DOI： 10.1007/s00259-013-2377-z

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

30 in total

1. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.

Authors: Orazio Schillaci; Ferdinando Calabria; Mario Tavolozza; Cristiana Ragano Caracciolo; Enrico Finazzi Agrò; Roberto Miano; Antonio Orlacchio; Roberta Danieli; Giovanni Simonetti
Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-10 Impact factor: 9.236

2. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Authors: Giampiero Giovacchini; Maria Picchio; Vincenzo Scattoni; Rita Garcia Parra; Alberto Briganti; Luigi Gianolli; Francesco Montorsi; Cristina Messa
Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-20 Impact factor: 9.236

3. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal: JAMA Date: 2005-07-27 Impact factor: 56.272

4. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.

Authors: Vera Graute; Nathalie Jansen; Christopher Ubleis; Michael Seitz; Markus Hartenbach; Michael Karl Scherr; Sven Thieme; Paul Cumming; Katharina Klanke; Reinhold Tiling; Peter Bartenstein; Marcus Hacker
Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-16 Impact factor: 9.236

Review 5. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer.

Authors: Maria Picchio; Elisabetta Giovannini; Cinzia Crivellaro; Luigi Gianolli; Nadia di Muzio; Cristina Messa
Journal: Radiother Oncol Date: 2010-08-12 Impact factor: 6.280

Review 6. Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors: Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal: J Nucl Med Date: 2008-11-07 Impact factor: 10.057

7. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.

Authors: Toni K Choueiri; Robert Dreicer; Alan Paciorek; Peter R Carroll; Badrinath Konety
Journal: J Urol Date: 2008-01-22 Impact factor: 7.450

Review 8. Lymph nodal metastases: diagnosis and treatment.

Authors: N Di Muzio; A Fodor; G Berardi; P Mapelli; L Gianolli; C Messa; M Picchio
Journal: Q J Nucl Med Mol Imaging Date: 2012-10 Impact factor: 2.346

9. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors: B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-22 Impact factor: 9.236

10. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.

Authors: Onisuru T Okotie; William J Aronson; Jeff A Wieder; Yen Liao; Fred Dorey; Jean B DeKERNION; Stephen J Freedland
Journal: J Urol Date: 2004-06 Impact factor: 7.450

14 in total

1. Writing PET into existence.

Authors: A Chiti; M Kirienko; E Incerti; M Picchio
Journal: Eur J Nucl Med Mol Imaging Date: 2013-09-27 Impact factor: 9.236

Review 2. Current use of PSMA-PET in prostate cancer management.

Authors: Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal: Nat Rev Urol Date: 2016-02-23 Impact factor: 14.432

Review 3. New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.

Authors: Asim Afaq; Deepak Batura; Jamshed Bomanji
Journal: Int Urol Nephrol Date: 2017-02-14 Impact factor: 2.370

4. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B Solomon; Jeremy C Durack; Jorge A Carrasquillo; Robert A Lefkowitz; Mithat Gonen; Jason S Lewis; Jason P Holland; Sarah M Cheal; Victor E Reuter; Joseph R Osborne; Massimo F Loda; Peter M Smith-Jones; Wolfgang A Weber; Neil H Bander; Howard I Scher; Michael J Morris; Steven M Larson
Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-21 Impact factor: 9.236

5. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and comparison with published data of [⁶⁸Ga]PSMA HBED-CC.

Authors: Christoph Berliner; Milena Tienken; Thorsten Frenzel; Yuske Kobayashi; Annabelle Helberg; Uve Kirchner; Susanne Klutmann; Dirk Beyersdorff; Lars Budäus; Hans-Jürgen Wester; Janos Mester; Peter Bannas
Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-28 Impact factor: 9.236

6. [Radionuclide therapy and diagnostics in urology].

Authors: W P Fendler; V Wenter; C G Stief; C Gratzke; P Bartenstein
Journal: Urologe A Date: 2015-07 Impact factor: 0.639

Review 7. [Focus on molecular imaging in prostate cancer].

Authors: L Michaud; K A Touijer
Journal: Prog Urol Date: 2016-09-20 Impact factor: 0.915

Review 8. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors: Hossein Jadvar
Journal: Abdom Radiol (NY) Date: 2016-05

9. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.

Authors: Christina Bluemel; Markus Krebs; Bülent Polat; Fränze Linke; Matthias Eiber; Samuel Samnick; Constantin Lapa; Michael Lassmann; Hubertus Riedmiller; Johannes Czernin; Domenico Rubello; Thorsten Bley; Saskia Kropf; Hans-Juergen Wester; Andreas K Buck; Ken Herrmann
Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794

Review 10. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.

Authors: Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber
Journal: Cancer Imaging Date: 2016-06-08 Impact factor: 3.909